Journal of Stem cell Research and Therapy

Dr. Hassan Dianat-Moghadam is an Assistant Professor in the Department of Genetics and Molecular Biology at Isfahan University of Medical Sciences, Iran. He specializes in medical biotechnology, cancer biology, and molecular genetics. His research focuses on cancer stem cells, immunotherapy, regenerative medicine, and nanobiotechnology for vaccine and therapeutic development. Dr. Dianat-Moghadam has published extensively in high-impact journals such as Cancer Letters, Stem Cell Research & Therapy, and International Immunopharmacology. He is also co-author of several academic books, including “Targeted Cancer Imaging” (Elsevier).

• Cancer Stem Cells
• Tumor Immunology
• Nanomedicine & Drug Delivery
• Oncolytic Virotherapy
• Molecular Oncology

• Research on cancer stem cells, tumor immunology, and targeted nanotherapies
• Development of gene therapy and CRISPR-based genome editing tools
• Studies on Leishmania vaccine design, oncolytic viruses, and nanocomposite scaffolds for tissue regeneration
• Collaboration with international researchers from Harvard Medical School, Tabriz University of Medical Sciences, and Tehran University of Medical Sciences
• Teaching graduate and Ph.D. courses in Molecular Biology, Cancer Genetics, and Gene Therapy

1. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. H Dianat-Moghadam, M Heidarifard, R Jahanban-Esfahlan, Y Panahi, et al. Journal of Controlled Release, 288, 62-83 (2018)
2. The role of circulating tumor cells in the metastatic cascade: biology, technical challenges, and clinical relevance. H Dianat-Moghadam, M Azizi, Z Eslami-S, LE Cortés-Hernández, et al. Cancers, 12(4), 867 (2020)
3. NK cells-directed therapies target circulating tumor cells and metastasis. H Dianat-Moghadam, A Mahari, M Heidarifard, N Parnianfard, et al. Cancer Letters, 497, 41-53 (2021) Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. M Keshavarz, ASM Nejad, M Esghaei, F Bokharaei-Salim, H Dianat-Moghadam, et al. Saudi Journal of Biological Sciences, 27(1), 47-52 (2020)
4. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. H Dianat-Moghadam, A Mahari, R Salahlou, M Khalili, M Azizi, et al. Stem Cell Research & Therapy, 13(1), 1-12 (2022)
5. TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. H Dianat-Moghadam, M Heidarifard, A Mahari, M Shahgolzari, et al. Pharmacological Research, 104716 (2020)
6. Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells. H Dianat-Moghadam, M Rokni, F Marofi, Y Panahi, M Yousefi. Journal of Cellular Physiology, 234(1), 259-273 (2019)
7. A review on the effect of nanocomposite scaffolds reinforced with magnetic nanoparticles in osteogenesis and healing of bone injuries. H Sadeghzadeh, H Dianat-Moghadam, D Bakhshayesh, A Rahmani, et al. Stem Cell Research & Therapy, 14(1), 1-17 (2023)
8. Engaging stemness improves cancer immunotherapy. H Dianat-Moghadam, M Sharifi, R Salehi, M Keshavarz, et al. Cancer Letters, 554, 216007 (2023) Multifunctional plant virus nanoparticles in the next generation of cancer immunotherapies. M Shahgolzari, H Dianat-Moghadam, S Fiering. Seminars in Cancer Biology, 86, 1076-1085 (2022)